Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats

Journal of Pineal Research

Volumn 34, Issue 4, 2003, Pages 282-287

  Jahovic, Nermina ^a   Çevik, Hülya ^a   Şehirli, A Özer ^a   Yeǧen, Berrak Ç ^a   Şener, Göksel ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

Glutathione; Kidney; Lipid peroxidation; Liver; Melatonin; Methotrexate; Myeloperoxidase activity

Indexed keywords

GLUTATHIONE; MALONALDEHYDE; MELATONIN; METHOTREXATE; MYELOPEROXIDASE; SODIUM CHLORIDE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEPATORENAL SYNDROME; KIDNEY PARENCHYMA; LIPID PEROXIDATION; LIVER; LIVER TOXICITY; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHYSIOLOGY; RAT; RAT STRAIN; SAMPLING;

EID: 0037404909     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-079X.2003.00043.x     Document Type: Article

References (56)

1. HERSH EM, WONG VG, HENDERSON ES, FREIRICH EJ. Hepatotoxic effects of methotrexate. Cancer 1966; 19:600-606.
2. HALL PM, JENNER MA, AHERN MJ. Hepatotoxicity in a rat model caused by orally administered methotrexate. Hepatology 1991; 14:906-910.
3. TOBIAS H, AUERBACH R. Hepatotoxicity of long term methotrexate therapy for psoriasis. Arch Intern Med 1973; 132:391-396.
4. ROENIGK HH, BERGFIELD WF, ST JACQUES R, OWENS FJ, HAWK WA. Hepatotoxicity of methotrexate in the treatment of psoriasis. Arch Dermatol 1971; 103:250-261.
5. KINTZEL PE. Anticancer drug-induced kidney disorders. Drug Safety 2001; 24:19-38.
6. IQBAL MP, SULTANA F, MAHBOOBALI N, PERVEZ S. Folinic acid protects against suppression of Growth by methotrexate in mice. Biopharm Drug Dispos 2001; 22:169-178.
7. SCHIFF MH, WHELTON A. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2000; 30:196-208.
8. GOTO E, TOMOJIRI S, OKAMOTO I, TANAKA K. Methotrexate poisoning with acute hepatorenal dysfunction. J Toxicol Clin Toxicol 2001; 39:101-104.
9. NEUMAN MG, CAMERON RG, HABER JA, KATZ GG, MALKEWCZ IM, SHEAR NH. Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatotoxicity. Clin Biochem 1999; 32:519-536.
10. CHLADEK J, MARTINKOVA J, SISPERA L. An in vitro study on methotraxate hydoxylation in rat and human liver. Physiol Res 1997; 46:371-379.
11. GALIVAN J, NIMEC Z, BALINSKA M. Regulation of methotrexate polyglutamate accumulation in vitro: effects of cellular folat content. Biochem Phannacol 1983; 32:3344-3347.
12. KAMEN BA, NYLEN PA, CAMITTA BM, BERTNO JR. Methotrexate accumulation and folate depletion in cell as a possible mechanism of chronic toxicity to the drug. Br J Hematol 1981; 49:355-360.
13. KREMER JM, GALIVAN J, STRECKFUSS A, KAMEN B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Arth Rheum 1986; 29:832-835.
14. JOLIVET J, COWAN KH, CURT GA, CLENDENINN NJ, CHABNER BA. The pharmacology and clinical use of methotrexate. N Engl J Med 1983; 309:1094-1104.
15. VOGEL WH, SNYDER R, SCHULMAN MP. The inhibition of dehydrogenases by folic acid and several of its analogs. Biochim Biophys Res Comm 1963; 10:97-101.
16. + dehydrogenases of HeLa cells: malic enzymes, 2-oxoluterate and isocitrate dehydrogenases. Cell Biochem Funct 1997; 15:259-264.
17. BABIAK RM, CAMPELLO AP, CARNIERI EG, OLIVEIRA MB. Methotrexate: pentose cycle and oxidative stress. Cell Biochem Funct 1998; 16:283-293.
18. REITER RJ, MAESTRONI GJM. Melatonin in relation to the antioxidative defense and immune systems: possible implications for cell and organ transplantation. J Mol Med 1999; 77:36-39.
19. CUZZOCREA S, COSTANTINO G, MAZZON E, MICALI A, DE SARRO A, CAPUTI AP. Beneficial effects of melatonin in a rat model of splanchnic artery occlusion and reperfusion. J Pineal Res 2000; 28:52-63.
20. REITER RJ, ACUNA-CASTROVIEJO D, TAN DX, BURKHART S. Free radical-mediated molecular damage. Ann NY Acad Sci 2001; 939:200-215.
21. TAN DX, CHEN LD, POEGGELER B, MANCHESTER LC, REITER RJ. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocrine J 1993; 1:57-60.
22. REITER RJ, TAN DX, OSUNA C, GITTO E. Actions of melatonin in the reduction of oxidative stress. J Biomed Sci 2000; 7:444-458
23. REITER RJ, TAN DX, MANCHESTER LC, QI W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species. A review of the evidence. Cell Biochem Biophys 2001; 34:237-256.
24. SENER G, SEHIRLI AO, ALTUNBAS HZ, PASKALOOLU K, AYANOGLU-DULGER G. Melatonin protects against gentamicin-induced nephrotoxicity in rats. J Pineal Res 2002; 32:231-236.
25. MCGINNES JE, PROCTOR PH, DEMOPOULOS HB, HOKANSON JA, KIRKPATRICK DS. Amelioration of cis-platinum nephrotoxicity by orgotein (superoxide dismutase). Phytiol Chem Phys 1978; 10:267-277.
26. AMIMOTO T, MATSURA T, KOYAMA SY, NAKANISHI T, YAMADA K, KAJIYAMA G. Acetaminophen-induced hepatic injury in mice: the role of lipid peroxidation and effects of pretreatment with coenzyme Q10 and alpha-tocopherol. Free Radic Biol Med 1995; 19:169-176.
27. KOUROUNAKIS AP, REKKA EA, KOUROUNAKIS PN. Antioxidant activity of guaiazulene and protection against paracetamol hepatotoxicity in rats. J Pharm Pharmacol 1997; 49:938-942.
28. BEUGE JA, AUST SD. Microsomal lipid peroxidation. Meth Enzymol 1978; 52:302-311.
29. BEUTLER E. Glutathione in Red Blood Cell Metabolism. A Manual of Biochemical Methods. Grune & Stratton, New York, 1975; pp. 112-114.
30. HILLEGAS LM, GRISWOLD DE, BRICKSON B, ALBRIGHTSON-WINSLOW C. Assesment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods 1990; 24:285-295.
31. SUGIYAMA S, HAYAKAWA M, KATO T, HANAKI Y, SHIMIZU K, OZAWA T. Adverse effects of anti-tumor drug, cisplatin, on rat kidney mitochondria: disturbances in glutathione peroxidate activity. Biochem Biophys Ret Comm 1989; 159:1121-1127.
32. ZHANG JG, ZHONG LF, ZHANG M, XIA YX. Protection effects of procaine on oxidative stress and toxicities of renal cortical slices from rats caused by cisplatin in vitro. Arch Toxicol 1992; 66:354-358.
33. VONEN B, MORLAND J. Isolated rat hepatocytes in suspension: potential hepatotoxic effects of six different drugs. Arch Toxicol 1984; 56:33-37.
34. VAN DEN BONGARD HJGD, MANHOT RAA, BEIJNEN JH et al. Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure. Cancer Chemother Pharmacol 2001; 47:537-540.
35. TSURUSAWA M, SAEKI K, FUJIMOTO T. Differential induction of apoptosis on human lymphoblastic leukemia Nalm-6 and Molt-4 cells by various antitumor drugs. Int J Hematol 1997; 66:79-88.
36. HEENEN M, LAPORTE M, DE GRAEF C. Methotrexate induces apoptotic cell death in human keratinocytes. Arch Dermatol Res 1998; 290:240-245.
37. ACUNA-CASTROVIEJO D, MARTIN M, MACIAS M et al. Melatonin, mitochondria and cellular bioenergetics. J Pineal Res 2001; 30:65-74,
38. KARBOWNIK M, REITER RJ, GARCIA JJ, TAN DX, QI W, MANCHESTER LC. Melatonin reduces rat hepatic macromolecular damage due to oxidative stress caused by δ-aminolevulinic acid. Biochim Biophys Acta 2000; 1523:140-146.
39. MORIOKA N, OKATANI Y, WAKATSUKI A. Melatonin protects against age-related DNA damage in the brains of female senescence-accelerated mice. J Pineal Res 1999; 27:202-209.
40. VIJAYALAXMI, MELTZ ML, REITER RJ, HERMAN TS. Melatonin and protection from genetic damage in blood and bone marrow: whole-body irradiation studies in mice. J Pineal Res 1999; 27:221-225.
41. SEWERYNEK E, MELCHIORRI D, REITER RJ, ORTIZ GG, LEWINSKI A. Lipopolysaccharide-induced hepatotoxicity is inhibited by the antioxidant melatonin. Eur J Pharmacol 1995; 293:327-334.
42. MELCHIORRI D, REITER RJ, SEWERYNEK E, CHEN LD, NISTICO G. Melatonin reduces kainate-induced lipid peroxidation in homogenates of different brain regions. FASEB J 1995; 9:1205-1210.
43. 2 induced lipid peroxidation in homogenates of different rat brain regions. J Pineal Res 1995; 19:51-56.
44. SUBRAMANIAM S, SHYA MALA DEVI CS. Vitamin E protects intestinal basolateralmembrane from CMF-induced damages in rat. Ind J Physiol Pharmacol 1995; 39:263-266.
45. HELMY M, SHOHAYEB M, HELMY MH, EL-BASSIOUNI EA. Antioxidants as adjuvant therapy in rheumatoid disease. A peliminary study. Arzneimittelforschung 2001; 51:293-298.
46. Ross D. Glutathione, free radicals and chemotherapeutic agents. Pharmacol Ther 1988; 37:231-249.
47. PRZYBTKOWSKI E, AVERILL-BATES DA. Correlation between glutathione and stimulation of the pentose phosphate cycle in situ in Chinese hamster ovary cells exposed to hydrogen peroxide. Arch Biochem Biophys 1996; 325:91-98.
48. GOLDMAN D. Analysis of the cytotoxic deteminants for methotrexate (NSC-740): a role for flee intracellular drug. Cancer Chemother Rep 1975; 6:51-61.
49. ROUSE K, NWOKEDI E, WOODLIFF JE, EPSTEIN J, KLIMBERG VS. Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism. Ann Surg 1995; 221:420-426.
50. MITCHELL JR, JALLOW DJ, GILLETTE JR, BRODIE BB. Drug metabolism at a cause of drug toxicity. Drug Metab Disposition 1973; 1:418-423.
51. BALIGA R, UEDA N, WALKER PD, SHAH SV. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 1999; 31:971-997.
52. PARKS DA, GRANGER DN. Ischemia-reperfusion injury: a radical view. Hepatology 1988; 8:680-682.
53. SULLIVAN GW, SAREMBOCK IJ, LINDEN J. The role of inflammation in vascular diseases. J Leukoc Biol 2000; 67:591-602.
54. SCHORNAGEL JH, MCVIE JG. The clinical pharmacology of methotrexate. Cancer Treat Rev 1983; 10:53-57.
55. BENOT S, GOBERNA R, REITER RJ, GARCIA-MAURINO S, OSUNA C, GUERRERO JM. Physiological levels of melatonin contribute to the antioxidant capacity of human serum. J Pineal Res 1999; 27:59-64.
56. REITER JR, TAN DX, SAINZ RM, MAYO JC, LOPEZ-BURILLO S, Melatonin: In reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002; 54:1299-1321.